DOCS
NEUTRAL
$24.01
Live
Doximity, Inc. · NYSE
Target $37.77
(+57.3%)
$20.55
52W Range
$76.51
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 26, 2026
Market cap
$4.52B
P/E
20.18
ROE
23.8%
Profit margin
37.5%
Debt/Equity
0.01
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
Doximity exhibits a stable financial foundation with a Piotroski F-Score of 4/9 and an exceptionally clean balance sheet characterized by near-zero debt. Despite elite gross margins (89.75%) and strong liquidity, the company is experiencing a severe valuation correction with a 1-year price decline of 57.4% and negative earnings growth (-16.20%). The current price of $24.01 trades at a significant premium to its Graham Number ($11.91) and Intrinsic Value ($8.33), indicating a disconnect between fundamental defensive value and market pricing. While analyst targets remain bullish, the combination of negative earnings momentum and bearish insider activity suggests caution.
Key Strengths
Exceptional Gross Margins (89.75%) and Profit Margins (37.54%)
Near-zero leverage with a Debt/Equity ratio of 0.01
Strong liquidity position with a Current Ratio of 6.63
Consistent track record of beating quarterly earnings estimates
Attractive PEG Ratio (0.66) suggesting undervaluation relative to long-term growth
Key Risks
Negative Earnings Growth (-16.20% YoY and -18.10% Q/Q)
Severe price momentum collapse (-64.1% over the last 6 months)
Bearish insider sentiment with consistent selling by the CFO and Directors
Significant premium to Graham Number ($11.91) and Intrinsic Value ($8.33)
Slowing revenue growth (9.80%) compared to historical high-growth expectations
AI Fair Value Estimate
Based on comprehensive analysis
$18.5
-22.9% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
40
Moderate
55
40
20
85
0
AI Verdict
Fundamentally Sound but Momentum Broken
Key drivers: Elite margins, Zero debt, Negative EPS growth, Severe price decline
Confidence
90%
Value
55/100
P/E 20.18, PEG 0.66, Graham $11.91
Positives
- Low PEG ratio
- Reasonable Forward P/E (14.81)
Watchpoints
- Price significantly exceeds Graham Number
- Price significantly exceeds Intrinsic Value
Future
40/100
Rev Growth 9.8%, EPS Growth -16.2%
Positives
- Positive revenue growth (9.8%)
Watchpoints
- Negative earnings growth
- Bearish technical trend
Past
20/100
1Y Change -57.4%, 6M Change -64.1%
Positives
- Strong history of EPS surprises
Watchpoints
- Catastrophic 1Y and 6M price performance
Health
85/100
Piotroski 4/9, Debt/Equity 0.01, Current Ratio 6.63
Positives
- Extremely low Debt/Equity
- High Current/Quick ratios
- Stable Piotroski F-Score
Watchpoints
- Piotroski score is stable (4/9) rather than strong (7-9)
Dividend
0/100
Yield N/A, Payout 0%
Positives
No standout positives identified.
Watchpoints
- No dividend payout
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$24.01
Analyst Target
$37.77
Upside/Downside
+57.3%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for DOCS and closest competitors.
Updated 2026-04-24
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
DOCS
Doximity, Inc.
Primary
|
-54.7% | -30.9% | -57.4% | -64.1% | -0.7% | -2.8% |
|
FOLD
Amicus Therapeutics, Inc.
Peer
|
+55.8% | +30.6% | +110.0% | +75.0% | +0.8% | +0.2% |
|
OPCH
Option Care Health, Inc.
Peer
|
+46.4% | -9.8% | -12.2% | +4.5% | -3.6% | -2.8% |
|
ALKS
Alkermes plc
Peer
|
+40.1% | +3.5% | -17.4% | +2.9% | -20.5% | -3.0% |
|
SHC
Sotera Health Company
Peer
|
-37.5% | -1.2% | +55.5% | +0.9% | +18.6% | +6.1% |
DOC
Doximity, Inc.
Primary
5Y
-54.7%
3Y
-30.9%
1Y
-57.4%
6M
-64.1%
1M
-0.7%
1W
-2.8%
FOL
Amicus Therapeutics, Inc.
Peer
5Y
+55.8%
3Y
+30.6%
1Y
+110.0%
6M
+75.0%
1M
+0.8%
1W
+0.2%
OPC
Option Care Health, Inc.
Peer
5Y
+46.4%
3Y
-9.8%
1Y
-12.2%
6M
+4.5%
1M
-3.6%
1W
-2.8%
ALK
Alkermes plc
Peer
5Y
+40.1%
3Y
+3.5%
1Y
-17.4%
6M
+2.9%
1M
-20.5%
1W
-3.0%
SHC
Sotera Health Company
Peer
5Y
-37.5%
3Y
-1.2%
1Y
+55.5%
6M
+0.9%
1M
+18.6%
1W
+6.1%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
20.18
Forward P/E
14.81
PEG Ratio
0.66
P/B Ratio
4.54
P/S Ratio
7.09
EV/Revenue
5.82
EV/EBITDA
15.12
Market Cap
$4.52B
Profitability
Profit margins and return metrics
Profit Margin
37.54%
Operating Margin
38.89%
Gross Margin
89.75%
ROE
23.82%
ROA
12.84%
Growth
Revenue and earnings growth rates
Revenue Growth
+9.8%
Earnings Growth
-16.2%
Q/Q Revenue Growth
+9.76%
Q/Q Earnings Growth
-18.1%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.01
Low debt
Current Ratio
6.63
Strong
Quick Ratio
6.0
Excellent
Cash/Share
$3.98
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.2B
Gross Margin
89.9%
Op. Margin
38.9%
Net Margin
33.3%
Total Assets
$1.2B
Liabilities
$0.2B
Equity
$1.0B
Debt/Equity
0.18x
Operating CF
$0.1B
CapEx
$-0.0B
Free Cash Flow
$0.1B
FCF Yield
96%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-13
$N/A
2026-02-05
$0.46
+2.9% surprise
2025-11-06
$0.45
+18.7% surprise
2025-08-07
$0.36
+17.2% surprise
Healthcare Sector Comparison
Comparing DOCS against 548 companies in the Healthcare sector
(30 bullish, 163 neutral, 355 bearish)
P/E Ratio
20.18
This Stock
vs
77.48
Sector Avg
-74.0%
(Discount)
Return on Equity (ROE)
23.82%
This Stock
vs
-89.9%
Sector Avg
-126.5%
(Below Avg)
Profit Margin
37.54%
This Stock
vs
-16.4%
Sector Avg
-328.9%
(Weaker)
Debt to Equity
0.01
This Stock
vs
2.71
Sector Avg
-99.6%
(Less Debt)
Revenue Growth
9.8%
This Stock
vs
126.74%
Sector Avg
-92.3%
(Slower)
Current Ratio
6.63
This Stock
vs
4.53
Sector Avg
+46.3%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
DOCS
Doximity, Inc.
|
NEUTRAL | $4.52B | 20.18 | 23.8% | 37.5% | $24.01 | |
|
FOLD
Amicus Therapeutics, Inc.
|
BEARISH | $4.54B | - | -11.6% | -4.3% | $14.47 | Compare |
|
OPCH
Option Care Health, Inc.
|
NEUTRAL | $4.45B | 22.32 | 15.2% | 3.7% | $28.34 | Compare |
|
ALKS
Alkermes plc
|
BEARISH | $4.63B | 19.41 | 14.7% | 16.4% | $27.76 | Compare |
|
SHC
Sotera Health Company
|
NEUTRAL | $4.65B | 60.37 | 15.4% | 6.7% | $16.3 | Compare |
DOCS
Doximity, Inc.
NEUTRAL
Mkt Cap
$4.5B
P/E
20.2
ROE
23.8%
Price
$24.01
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-10 | SITARAM SIDDHARTH | Chief Financial Officer | Sale | 2,427 | $51,185 |
| 2026-04-10 | SITARAM SIDDHARTH | Chief Financial Officer | Stock Award | 5,000 | - |
| 2026-03-10 | SITARAM SIDDHARTH | Chief Financial Officer | Sale | 2,319 | $58,833 |
| 2026-03-10 | SITARAM SIDDHARTH | Chief Financial Officer | Stock Award | 5,000 | - |
| 2026-03-03 | WAMPLER KIRA SCHERER | Director | Sale | 2,000 | $52,000 |
| 2026-03-03 | WAMPLER KIRA SCHERER | Director | Stock Award | 2,000 | - |
| 2026-02-13 | BRYSON ANNA COLLINS | Chief Financial Officer | Stock Award | 152,258 | - |
| 2026-02-13 | SITARAM SIDDHARTH | Officer | Stock Award | 10,376 | $8,167 |
| 2026-02-10 | SITARAM SIDDHARTH | Chief Financial Officer | Sale | 2,282 | $63,622 |
| 2026-02-10 | SITARAM SIDDHARTH | Chief Financial Officer | Stock Award | 5,000 | - |
| 2026-02-02 | WAMPLER KIRA SCHERER | Director | Sale | 2,000 | $74,660 |
| 2026-02-02 | WAMPLER KIRA SCHERER | Director | Stock Award | 2,000 | - |
| 2026-01-02 | WAMPLER KIRA SCHERER | Director | Sale | 2,000 | $89,300 |
| 2026-01-02 | WAMPLER KIRA SCHERER | Director | Stock Award | 2,000 | - |
| 2025-12-01 | WAMPLER KIRA SCHERER | Director | Sale | 2,000 | $101,420 |
SITARAM SIDDHARTH
Chief Financial Officer
2026-04-10
2,427 shares
·
$51,185
SITARAM SIDDHARTH
Chief Financial Officer
2026-04-10
5,000 shares
SITARAM SIDDHARTH
Chief Financial Officer
2026-03-10
2,319 shares
·
$58,833
SITARAM SIDDHARTH
Chief Financial Officer
2026-03-10
5,000 shares
WAMPLER KIRA SCHERER
Director
2026-03-03
2,000 shares
·
$52,000
WAMPLER KIRA SCHERER
Director
2026-03-03
2,000 shares
BRYSON ANNA COLLINS
Chief Financial Officer
2026-02-13
152,258 shares
SITARAM SIDDHARTH
Officer
2026-02-13
10,376 shares
·
$8,167
SITARAM SIDDHARTH
Chief Financial Officer
2026-02-10
2,282 shares
·
$63,622
SITARAM SIDDHARTH
Chief Financial Officer
2026-02-10
5,000 shares
WAMPLER KIRA SCHERER
Director
2026-02-02
2,000 shares
·
$74,660
WAMPLER KIRA SCHERER
Director
2026-02-02
2,000 shares
WAMPLER KIRA SCHERER
Director
2026-01-02
2,000 shares
·
$89,300
WAMPLER KIRA SCHERER
Director
2026-01-02
2,000 shares
WAMPLER KIRA SCHERER
Director
2025-12-01
2,000 shares
·
$101,420
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
8-K
10-Q
8-K
8-K
10-Q
8-K
8-K
10-Q
8-K
Data sourced from SEC EDGAR. AI summaries generated automatically.
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
22 analysts
Truist Securities
2026-04-20
Buy
Hold
B of A Securities
2026-04-16
Buy
Buy
Keybanc
2026-04-13
Overweight
Overweight
Goldman Sachs
2026-04-09
Neutral
Neutral
Evercore ISI Group
2026-04-08
Outperform
In-Line
Freedom Capital Markets
2026-03-18
Buy
RBC Capital
2026-03-09
Outperform
Outperform
JP Morgan
2026-02-20
Neutral
Neutral
Piper Sandler
2026-02-20
Overweight
Overweight
Barclays
2026-02-11
Overweight
Overweight
Past News Coverage
Recent headlines mentioning DOCS from our newsroom.
Newest → oldest
No matching news yet.